Skip to main content
SpringerLink
Log in

Metastasiertes Nierenzellkarzinom

Folgetherapien nicht vorenthalten

  • panorama
  • Published:
best practice onkologie Aims and scope

Nach Prof. Dr. Manuela Schmidinger, Wien, Österreich, ist das metastasierte Nierenzellkarzinom (mRCC) keine Erkrankung mehr, die sich nur palliativ behandeln lässt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Meet-the-Expert der Pfizer Deutschland GmbH

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    fk

Authors
  1. fk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

fk Folgetherapien nicht vorenthalten. best practice onkologie 9, 31 (2014). https://doi.org/10.1007/s11654-014-0561-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0561-7

Search

Navigation